Abstract
Multiple myeloma (MM) is a B-cell neoplastic disease characterized by excessive number of abnormal plasma cells in the bone marrow and overproduction of intact monoclonal immunoglobulins or light chain (Bence Jones) proteins. The average age of onset is about 60 years and occurs more frequently in men than women. MM is preceded by a premalignant condition termed monoclonal gammopathy of undetermined significance (MGUS). Age is an important prognostic factor, and with each decade from the age of 50 years to over the age of 80, the overall survival declines. This review will provide an update on the clinical management of multiple myeloma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Haemat Oncol Clin North Am. 1992;6:225–47.
Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29–40.
Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J Managed Care Pharm Supplement. 2008;14(7):S7–S11.
Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301–18.
Dimopoulos MA, Kastritis E, Rosinol L, Blake J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma bone disease. Haematol Oncol Clin North Am. 2007;21:1035-1-9.
Anderson KC,Carrasco RD. Pathogenesis of myeloma. Annual Rev Pathol Mech Dis. 2011;6:24.
Kyle RA. “Benign” monoclonal gammopathy-after 20–35 years of follow up. Mayo Clin Proc. 1993;68:26–36.
Firkin F. Screening for multiple myeloma. Aust Prescriber. 2009;32:92–94.
Ludwig H, Bolejack V, Crowley J, Blade J, San Miguel J, Kyle RA. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2008;28:1599–160.
Alexanian RA, Balcerzak S, Bonnet JD, Gehan E, Haut A, Hewlett JS, et al. Prognostic factors in multiple myeloma.Cancer.1975;36:1192–201.
Durrie BGM, Salmon SE, Moon TF. Pretreatment tumour mass, cell kinetics and prognosis in multiple myeloma. Blood. 1980;55:364–72.
Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13 Suppl. 2:56–63.
Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-Reactive protein and beta-2 microglobulin produce a simple powerful myeloma staging system. Blood 1992;80(3):733–7.
Pelliniemi TT, Irjala K, Mattila K, PalkkiK, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukaemia Group. Blood. 1995;85(3):765–71.
Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–854.
Greipp PR, Miguel JS, Durie BGM, Crawley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
Cassuto JP, Krebs BJ, Vit G. Beta-2 microglobulin a tumour marker of lymphoproliferative disorders. Lancet. 1978;2:108–109.
Bataille R, Durrie BGM,Grenier J. Serum beta 2 microglobulin and similar markers in multiple myeloma : a reliable marker for staging. Br J Haematol. 1093;55:439–44.
Norfolk D,Child JA, Cooper EH, Kerruish S,Ward AM. Serum beta-2 microglobulin in myelomatosis. Potential value in stratification and monitoring. Br J Cancer. 1980;42(4):510–515.
Attal M, Haroussaue JL, Stoppa A M, Sotto JJ, Fuzibet JG, Rosal JF, et al. A prospective randomized trial of autologous bone marrow transplantation for multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med. 1996;335:91–97.
Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet J-O, et al. Intergroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2004; 350:1655–1664.
Hoarousseau J-L. Multiple myeloma in the elderly: When to treat. Whe to go to transplant. 2010. http://www.cancernetwork.com/mulitiple-myeloma/multiple-myeoma-elderly –when -treat.
Osborn M, Horvath N, To LB. New drugs for multiple myeloma. Aust Prescriber. 2009;32:95–98.
Joshua DE. Multiple myeloma: the present and the future. AJA. 2005;183:34418.
Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benbonbker L, et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myeloma. Haematologica. 2005;90 Suppl 1:17.
Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004:350:1655–1664.
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley N, et al. Zoledronic acid reduces skeletal –related events in patients with osteolytic metastases. Cancer. 2001;91:1191–1200.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2018). Immunoproliferative Disorders. In: Geriatric Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-33434-9_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-33434-9_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33433-2
Online ISBN: 978-3-319-33434-9
eBook Packages: MedicineReference Module Medicine